Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1sMeirong Zang, Wen Zhou|Oncogenesis|2020Cited by 13
799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-AchieveRemo Panaccione, Peter Higgins, Geert D’Haens et al.|Gastroenterology|2019Cited by 11
OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE studyWilliam J. Sandborn, Edward V. Loftus, Stefan Schreiber et al.|Journal of Crohn s and Colitis|2019Cited by 9
P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinibSubrata Ghosh, Julián Panés, Édouard Louis et al.|Journal of Crohn s and Colitis|2019Cited by 6
800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve StudyWilliam J. Sandborn, Edward V. Loftus, Stefan Schreiber et al.|Gastroenterology|2019Cited by 4